A detailed history of National Bank Of Canada transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, National Bank Of Canada holds 1,704 shares of ABUS stock, worth $5,606. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,704
Previous 1,704 -0.0%
Holding current value
$5,606
Previous $6,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.12 - $4.56 $3,138 - $4,587
-1,006 Reduced 37.12%
1,704 $6,000
Q2 2024

Aug 02, 2024

BUY
$2.52 - $3.63 $2,520 - $3,630
1,000 Added 58.48%
2,710 $8,000
Q1 2024

May 13, 2024

SELL
$2.26 - $2.92 $248 - $321
-110 Reduced 6.04%
1,710 $4,000
Q3 2023

Oct 10, 2023

SELL
$1.9 - $2.27 $570 - $681
-300 Reduced 14.15%
1,820 $3,000
Q4 2022

Jan 24, 2023

BUY
$1.91 - $2.85 $573 - $855
300 Added 16.48%
2,120 $0
Q4 2021

Jan 24, 2022

BUY
$3.11 - $4.61 $5,660 - $8,390
1,820 New
1,820 $7,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $493M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.